Overview

• HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary told 22 Republican attorneys general the agency is conducting its own review of mifepristone’s safety, efficacy and current Risk Evaluation and Mitigation Strategy using real‑world evidence.
• Their letter cites a non–peer‑reviewed Ethics and Public Policy Center analysis claiming nearly 11% serious adverse events, a figure widely criticized by researchers and medical groups compared with FDA data showing about five deaths per 1 million users and low complication rates.
• House Republicans, led by Rep. Mary Miller, introduced a bill to reinstate in‑person dispensing, require physician prescribing and in‑person checkups, effectively ending telehealth and mail delivery; the measure mirrors legislation backed by Sen. Josh Hawley.
• Abortion‑rights advocates call the review political interference that could be used to restrict access, while anti‑abortion groups praised the move; the FDA has not given a timeline for conclusions or potential changes.
• Medication abortion now accounts for roughly two‑thirds of U.S. abortions, and California moved to reinforce access by allowing anonymous prescribing, mandating insurance coverage for mifepristone and expanding legal protections for providers.